Примери за използване на Was co-administered на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Furthermore, increases in INR values have been reported when duloxetine was co-administered with warfarin.
In all infant studies, Prevenar 13 was co-administered with routine paediatric vaccines(see section 4.5).
Similarly, the pharmacokinetics of irinotecan were unchanged when cetuximab was co-administered.
In clinical studies,PRILACTONE was co-administered with furosemide and pimobendan without evidence of associated adverse reactions.
Atazanavir and fluconazole concentrations were not significantly modified when Atazanavir/ritonavir was co-administered with fluconazole.
When Zontivity was co-administered with prasugrel, no clinically significant pharmacokinetic interaction was demonstrated.
In clinical trials, there was no evidence of safety concerns when dronedarone was co-administered with statins metabolised by CYP 3A4.
Pantoprazole When Pradaxa was co-administered with pantoprazole, a decrease in the dabigatran AUC of approximately 30% was observed.
Exposure to erythromycin and midazolam was increased approximately 1.3 and2.4 fold, respectively, when each was co-administered with netupitant.
When Zontivity was co-administered with warfarin, there were no alterations in the pharmacokinetics or pharmacodynamics of warfarin.
Increased liver weight andgallstones have been reported in repeated dose studies in which cholic acid was co-administered with cholesterol.
When telmisartan was co-administered with digoxin, median increases in digoxin peak plasma concentration(49%) and in trough concentration(20%) were observed.
Plasma concentrations of atorvastatin and its active metabolites were lower(by approx. 25%)when colestipol was co-administered with{PRODUCT NAME}.
When telmisartan was co-administered with digoxin, median increases in digoxin peak plasma concentration(49%) and in trough concentration(20%) were observed.
No significant interactions were shown when warfarin(25 mg), which is metabolised by CYP2C9, ordigoxin(0.375 mg) was co-administered with vardenafil(20 mg).
In clinical studies, cobicistat was co-administered with atazanavir or darunavir under fed conditions, in accordance with the Summary of Product Characteristics for these agents.
In the remaining nine trials(Europe, Canada, USA, Latin America, Singapore, South-Africa),Rotarix was co-administered with routine paediatric vaccines(see section 4.5).
When dabigatran etexilate 150 mg once daily was co-administered with dronedarone 400 mg twice daily, the dabigatran AUC0-24, and Cmax were increased by 100% and 70%, respectively.
In a drug interaction study, carbamazepine plasma concentrations were decreased when carbamazepine was co-administered with efavirenz(see section 4.5).
This is supported by studies in rats where topiramate was co-administered with probenecid, and a significant increase in renal clearance of topiramate was observed.
Interaction with medicinal products metabolized by CYP2D6 In 23 healthy subjects, the concentration of desipramine,a CYP2D6 substrate, was unaffected when 25 mg of temsirolimus was co-administered.
No clinically significant pharmacodynamic interactions were observed when clopidogrel was co-administered with atenolol, nifedipine, or both atenolol and nifedipine.
When Cholestagel was co-administered with statins in clinical studies, an expected add-on LDL-C lowering effect was observed, and no unexpected effects were observed.
In a clinical study, naltrexone/ bupropion(32 mg naltrexone hydrochloride /360 mg bupropion hydrochloride daily) was co-administered with a 50 mg dose of metoprolol(a CYP2D6 substrate).
When APTIVUS, co-administered with low dose ritonavir, was co-administered with 20 ml of aluminium- and magnesium-based liquid antacid, tipranavir AUC12h, Cmax and Cmin were reduced by 25-29%.
A significant decrease in plasma concentrations of atazanavir and a marked increase of tipranavir and ritonavir concentrations was observed when APTIVUS,associated with low dose ritonavir, was co-administered with atazanavir(see section 4.5).
No significant interactions were shown when sildenafil(50 mg) was co-administered with tolbutamide(250 mg) or warfarin(40 mg), both of which are metabolised by CYP2C9.
When erlotinib was co-administered with ciprofloxacin, a moderate CYP1A2 inhibitor, the erlotinib exposure[AUC] increased significantly by 39%, while no statistically significant change in Cmax was found.
However, a 25% decrease in peak international normalised ratio(INR)was observed when A771726 was co-administered with warfarin as compared with warfarin alone.
When ketoconazole was co-administered with trabectedin, the plasma exposure of trabectedin was increased by approximately 21% for Cmax and 66% for AUC, but no new safety concerns were identified.